Drugs Controller General of India: News
Why permission for eye drop to replace spectacles was revoked
The Drugs Controller General of India (DCGI) has suspended the approval previously granted to Entod Pharmaceuticals, for the production and sale of its new eye drop.
India gets first vision-correcting eye drops: How they work
Entod Pharmaceuticals has introduced PresVu, a much-needed solution for individuals suffering from presbyopia.
Uzbekistan cough syrup deaths: India allows company to reopen factory
The Uttar Pradesh government has allowed Marion Biotech, which manufactured the cough syrup responsible for the deaths of 65 kids in Uzbekistan last year, to restart most production, Reuters reported.
Why is Abbott India recalling its antacid Digene gel?
Abbott India has voluntarily recalled batches of its antacid Digene Gel manufactured at the company's Goa facility, following an advisory from the Drugs Controller General of India (DCGI).
Serum Institute seeks DCGI's approval for Covovax as booster dose
The Serum Institute of India (SII) has sought the Drugs Controller General of India's (DCGI) approval to roll out its Covovax in the market as a booster dose for adults.
Lumpy skin disease kills 67,000 cattle across India: Details here
The lumpy skin disease (LSD) has claimed the lives of about 67,000 cattle in seven Indian states and one union territory, as per the data furnished by the central government on Monday.
Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech
The phase 3 clinical trials of Bharat Biotech's COVID-19 nasal vaccine have been completed, according to Dr. Krishna Ella, the company's Chairman and Managing Director.
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years.
COVAXIN likely to get approval for children above 2yrs: Report
Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.
Biological E's Corbevax vaccine approved for children aged 12-18 years
The Drugs Controller General of India (DCGI) has granted an emergency use authorization (EUA) to Corbevax—a COVID-19 vaccine developed by Hyderabad-based Biological E—for use in children aged between 12 and 18 years.
COVAXIN, Covishield will now be available in hospitals and clinics
The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.
New anti-COVID drug may cost up to Rs. 3,000: Report
Molnupiravir, an antiviral medication, is projected to cost between Rs. 2,000 and Rs. 3,000 for a full treatment.
J&J vaccine's 1cr doses ready for export after CDL nod
American firm Johnson & Johnson's COVID-19 vaccine shots, manufactured in India by Hyderabad-based Biological E, are ready for export, News18 reported.
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday.
India's drug regulator approves study on mixing Covishield, COVAXIN jabs
The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.
India offered 7.5mn doses of Moderna vaccine under COVAX program
India has been offered 7.5 million doses of Moderna's COVID-19 vaccine through the COVAX global vaccine sharing program, but it is not clear when the jabs will arrive in the country as a consensus on the indemnity clause is yet to be reached, sources said.
Hetero seeks Emergency Use Authorization for Molnupiravir in India
The use of Molnupiravir, an experimental oral drug having antiviral properties, has resulted in early recovery of COVID-19 patients with mild symptoms when compared to standard treatment during Phase III clinical trials, Hetero said on Friday citing interim data.
DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG
Pharmaceutical firm Mankind Pharma on Thursday announced that it has received approval from the Defence Research and Development Organisation (DRDO) to manufacture and market the COVID-19 drug 2-Deoxy-D-Glucose or 2-DG.
Expert panel says no to Covovax's children trials in India
A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.
Zydus applies for approval of its 3-dose, needle-free COVID-19 vaccine
Zydus Cadila, the Gujarat-based drug firm, has applied for the Emergency Use Authorization (EUA) of its COVID-19 vaccine to the Drugs Controller General of India (DCGI), the company said today.
Bharat Biotech submits COVAXIN phase-3 trial data, review meet today
Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).
COVID-19: DCGI gives approval for phase-2 clinical trials of Colchicine
India's top drug regulator - the Drugs Controller General of India (DCGI) - has given approval to carry out phase-2 clinical trials of Colchicine on COVID-19 patients.
Foreign COVID-19 vaccines exempted from local trials, batch testing
The Drugs Controller General of India has scrapped the requirement of local trials for foreign-made coronavirus vaccines - a key move to upscale the dwindling COVID-19 vaccinations in the country.
DRDO's antibody detection kit DIPCOVAN approved by the DCGI
The Drugs Controller General of India (DCGI) has approved an antibody detection kit developed by a laboratory of the Defence Research and Development Organisation (DRDO), reports say.
DRDO's anti-coronavirus drug cleared for emergency use by DCGI
The Drugs Controller General of India (DCGI) has approved the emergency use of an anti-coronavirus drug developed by a laboratory of the Defence Research and Development Organisation (DRDO) to treat moderate to severe patients, reports say.
Expert panel recommended against granting EUA to Pfizer's vaccine: Officials
Just two days before pharma major Pfizer announced the withdrawal of its application for emergency use authorization of its COVID-19 vaccine in India, an expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage.
Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial
An expert panel, Central Drugs Standard Control Organisation, (CDSCO) on Tuesday recommended granting permission for conducting the Phase I clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.
Days after participating in vaccine trial, man dies in Bhopal
A 42-year-old volunteer named Deepak Marawi, from Bhopal in Madhya Pradesh died nearly ten days after he participated in the clinical trial for COVAXIN held at a private hospital, its vice-chancellor said on Saturday.
Global leaders hail India's scientific innovation to combat COVID-19
Global leaders have lauded India's leadership in scientific innovation and decisive action to combat the COVID-19 pandemic.
All you need to know about vaccines approved in India
Earlier on Sunday, the Drugs Controller General of India (DCGI) announced the issuance of emergency approval to two COVID-19 vaccines for restricted use in India: Covishield and COVAXIN.
SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
Two COVID-19 vaccines, Covishield and COVAXIN, have been granted emergency approval for use in India, the Drugs Controller General of India (DCGI) Dr. VG Somani said on Sunday.
Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod
A government-appointed panel on Saturday recommended emergency-use authorization (EUA) to the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech.
India set to start COVID-19 vaccination; panel approves Oxford vaccine
In a development that will soothe the coronavirus-battered nation, the Central Drugs Standard Control Organization (CDSCO) panel on Friday gave approval to the vaccine developed by the University of Oxford and British-pharma giant AstraZeneca.
India could start 2021 with COVID-19 vaccine in hand: DCGI
The approval for a COVID-19 vaccine in India is likely just around the corner, with the Drugs Controller General of India, Dr. VG Somani, indicating the country might begin the New Year with a vaccine in hand.
Pfizer seeks emergency approval for COVID-19 vaccine in India
United States-based pharmaceutical giant Pfizer has sought emergency approval for its COVID-19 vaccine from India's drug regulator.
AIIMS to submit proposal for COVAXIN's phase three trials soon
By early next week, AIIMS will submit a proposal to start the third phase of clinical trials of COVAXIN, a vaccine against coronavirus being developed by Bharat Biotech.
Oxford's coronavirus vaccine could be available by December: Adar Poonawalla
In a welcome piece of development, Serum Institute of India's CEO Adar Poonawalla said on Wednesday that the coronavirus vaccine, being developed by Oxford University, could be available for use in India by December 2020.
Coronavirus vaccine to reach 25 crore Indians by mid-2021: Government
The Indian government is planning to provide vaccines to roughly 25 crore people by July 2021, Union Health Minister Dr. Harsh Vardhan said on Sunday.
Bharat Biotech signs deal for nasal COVID-19 vaccine: Details here
In a major move, Bharat Biotech has signed an agreement to license a nasal COVID-19 vaccine developed by the Washington University School of Medicine in St. Louis, United States.
Coronavirus: What is the 'Feluda' test? How does it work?
The Drugs Controller General of India (DCGI) has approved for commercial launch of a CRISPR-based test for COVID-19, called 'Feluda'.
SII gets nod for Oxford COVID vaccine phase 2/3 trials
The Serum Institute of India (SII) has gotten the approval to conduct phase 2 and 3 human clinical trials of the COVID-19 vaccine candidate developed by Oxford University.
You can enroll for AIIMS's COVID-19 vaccine trials: Here's how
India's indigenous COVID-19 vaccine candidate, COVAXIN, is set to go into human trials at AIIMS Delhi.
Expert panel sets conditions, ICMR's COVAXIN August-15 target looks unachievable
On July 2, the Indian Council of Medical Research (ICMR) revealed its plans to launch COVAXIN, the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech and ICMR, by August 15.
India's second COVID-19 vaccine cleared for human trials: Details here
India is picking up pace to develop a preventive vaccine for COVID-19, the novel coronavirus disease.
Glenmark launches COVID-19 drug FabiFlu at Rs. 103 per tablet
Glenmark Pharmaceuticals Ltd. launched the antiviral drug favipiravir on Saturday for the treatment of mild to moderate cases of COVID-19.
Remdesivir reportedly approved for COVID-19 treatment in India
Remdesivir has been approved by India's top drug regulator for "restricted emergency use" on COVID-19-infected adults and children.
#GoodNews: Pune's Mylab approved to make COVID-19 test kits
In a major development, Pune-based molecular diagnostics company Mylab Discovery Solutions has been given the go-ahead to develop testing kits for the novel coronavirus disease (COVID-19).
GSK recalls popular antacid Zinetac amid concerns over cancer-causing substance
Amid an ongoing probe into Ranitidine's reported cancer-causing impurities, GlaxoSmithKline Pharmaceuticals Limited (GSK) has recalled Ranitidine-based antacid Zinetac (150mg and 300mg) in India and other markets.
India may have a vaccine for dengue by 2019-end
We might have a vaccine for Dengue by the end of 2019.